Company Crescita Therapeutics Inc. Other OTC
Equities
CRRTF
CA2258471028
Pharmaceuticals
Business Summary
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Commercial Skincare
59.6
%
| 8 | 34.1 % | 10 | 59.6 % | +30.14% |
Manufacturing and Services
28.8
%
| 14 | 58.2 % | 5 | 28.8 % | -63.13% |
Licensing and Royalties
11.6
%
| 2 | 7.7 % | 2 | 11.6 % | +12.78% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Canada
66.9
%
| 10 | 41.6 % | 12 | 66.9 % | +19.74% |
United States
23.8
%
| 12 | 51.6 % | 4 | 23.8 % | -65.58% |
Rest-of-World
9.2
%
| 2 | 6.8 % | 2 | 9.2 % | +1.38% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Serge Verreault
CEO | Chief Executive Officer | - | - |
Jose DaRocha
DFI | Director of Finance/CFO | - | 17-08-31 |
Daniel Chicoine
CHM | Chairman | 70 | 16-02-29 |
Wade Hull
CTO | Chief Tech/Sci/R&D Officer | - | 16-02-29 |
Linda Kisa
IRC | Investor Relations Contact | - | - |
Ramirez Medina
PRN | Corporate Officer/Principal | - | 21-05-31 |
Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 16-02-29 | |
Daniel Chicoine
CHM | Chairman | 70 | 16-02-29 |
John London
BRD | Director/Board Member | - | 16-02-29 |
Deborah Trudeau
BRD | Director/Board Member | - | 21-11-09 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 19,541,391 | 17,448,741 ( 89.29 %) | 0 | 89.29 % |
Company contact information
Crescita Therapeutics, Inc.
2805 Place Louis-R Renaud
H7V 0A3, Laval
+
http://www.crescitatherapeutics.comSector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
+32.23% | 694B | |
+29.39% | 593B | |
-1.59% | 371B | |
+19.98% | 331B | |
+7.21% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.68% | 169B |